Business and Commercialisation of novel marine proteinhydrolysates
SuReMetS project consortium has generated a significant amount of scientific knowledge with respect to, protein hydrolysates produced from sustainable marine resources and their role in the management of metabolic syndromes. All the novel protein hydrolysates developed were assessed and ranked as per their potential of DPP-IV inhibitory activity, GLP-1 secretory activity, anti-inflammatory activity and antioxidant activity via in vitro studies. An animal trial is ongoing to assess and reconfirm the potential of the most promising protein hydrolysates developed under this project.
Bio-marine Ingredients Ireland Limited (BII) as an industrial partner, has successfully demonstrated industrial-scale bio-refining of the most promising biomasses studied under the SuReMetS project with the higher TRL (from TRL-2 to TRL-6). However, there was no work package assigned related to the “development of commercialization strategy of new protein ingredients” in the ongoing SuReMets project. Hence, BII intends to add more financial impact to the new protein ingredients developed under the SuReMeS project by developing a commercialization strategy and presenting their applications towards not only for metabolic syndrome but also for different segments of the global market viz., infant formula, sports nutrition, clinical nutrition and pet nutrition. The Global protein hydrolysates market is forecast to reach €3.7 Billion by 2024 growing at a CAGR of 6.1% and the global protein Ingredients market is anticipated to experience a CAGR of 9.1% from 2020 to 2027 to reach $76bn value including human & pet food ingredients. BII is the only industry partner of this consortium that has the potential to produce these marine protein hydrolysates at an industrial scale and take these new protein hydrolysates to a global market of protein ingredients using their existing base of customers and distributors based in Asia Pacific, North America, and Europe.